[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,525
Citations 0
Comment & Response
June 23/30, 2015

Dosing Recommendations for New Oral Anticoagulants

Author Affiliations
  • 1Boehringer Ingelheim GmbH, Ingelheim, Germany
JAMA. 2015;313(24):2496. doi:10.1001/jama.2015.5739

To the Editor Dr Powell1 advocated for individualized therapy for the new direct-acting oral anticoagulants (DOACs) based on defined therapeutic target ranges simulated from phase 3 trials.

The idea of therapeutic drug monitoring is derived from the monitoring of vitamin K antagonists (VKAs), which have a narrow therapeutic window. Because of the multiple interactions of VKAs, therapeutic drug monitoring is the only possible way to ensure patient safety.

First Page Preview View Large
First page PDF preview
First page PDF preview
×